Spinoff Companies and Licensed Technologies

Can-Fite BioPharma

Can-Fite BioPharma has an advanced pipeline of proprietary drug candidates in phase II and phase III clinical development that address inflammatory, liver, and metabolic diseases.

Can-Fite's platform technology utilizes the Gi protein-associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory, cancer, and other pathological body cells, whereas low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention.

The company's compounds have strong anti-inflammatory and anticancer effects.

Exero Medical

Exero Medical is developing a biodegradable wireless sensor for early detection of anastomotic leaks following GI surgery.

Anastomotic leaks are a common, life-threatening complication of GI surgeries, such as colorectal and bariatric surgeries.

The system is designed to prevent complications by warning physicians of potential leaks, allowing early intervention, which is key to a favorable outcome.

In December 2020, the FDA granted Breakthrough Device Designation to the wireless system.

Prolor – Opko

Prolor Biotech developed longer-acting proprietary versions of already approved therapeutic proteins. The CTP technology is applicable to virtually all proteins. In addition to its long-acting version of human growth hormone, PROLOR also developed long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity.

Prolor was acquired by OPKO on 2013 in a transaction valued at approximately $480 million. OPKO signed a worldwide collaboration agreement with Pfizer Inc. for the development and commercialization of somatrogon, a once-weekly long-acting recombinant human growth hormone.

BeyonAir

Steadfast in their commitment to harness the power of nitric oxide, Beyond Air (former AIT) are revolutionizing care to transform patients lives.

The combined product of drug and device is a revolutionary respiratory targeted system designed to safely and effectively deliver NO (Nitric Oxide) to non-intubated patients (home or hospital) in order to treat severe lung infections, including bronchiolitis and cystic fibrosis. The company conducted several Phase 2 trials. Improvement in oxygenation, significant reduction of time to discharge and reduction of bacterial loads were observed.

EyeYon

EyeYon Medical is a pioneer in ophthalmologic medical devices, focusing on developing cornea-focused sight-saving solutions for more than a decade. The company believes in challenging technology barriers to save the vision of millions of eyes worldwide. EyeYon has two products:

Hyper-CL™ Therapeutic Soft Contact Lens - the market’s first ocular drug depot system in the form of a non-invasive, comfortable, and easy-to-use contact lens.
EndoArt® Artificial Corneal Endothelial Layer - the first synthetic implant to treat corneal edema, saving vision and restoring function by creating a new type of corneal availability.

Zebra Medical / NANOX

Zebra Medical Vision solutions provide automated analysis of millions of real-time and retrospective imaging studies. This allows early identification of disease, and implementation of decision support tools for population health and risk management.

Zebra's high-performance software has secured multiple regulatory approvals, such as FDA and CE, and is installed in hospitals globally. Zebra was named one of Fast Company's Top-5 AI and Machine Learning companies.
Zebra was acquired by Nanox.

Cathworks

Cathworks developed FFRangio for the interventional cardiology market and is focused on improving the utilization of coronary angiography data to ratify measurement-based medicine in the cath lab.

The CathWorks FFRangio® System has received United States 510(k) clearance, Europe CE approval, Israel Amar approval, and Japan PMDA approval.

A privately-held Israeli company established in 2013, CathWorks signed a copromotion agreement with Medtronics in 2022 in a path towards acquisition.

MediWound

Mediwound (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The company develops, manufactures and globally commercializes innovative products in the fields of severe burn and chronic wound management.
MediWound’s goal is to provide its innovative burn wound eschar removal agent, NexoBrid™.

NexoBrid™, is indicated in Europe for removal of eschar in adults with deep partial- and full-thickness thermal burns.
NexoBrid™ successfully completed clinical development in hospitalized burn wounds and was launched throughout Europe.

NGS

Nutritional Growth Solutions (NGS) creates nutritional supplements that are scientifically formulated by paediatric doctors, patented, and clinically proven to support growth development in children.

The patented formula is sold globally under various brands, including a shake formula and nutrition bar through pharmacies and health food stores, distributors as well as online through the Healthy Heights® website, T-Mall Global (China) and Amazon in five countries – China, United States, Italy, Canada, Israel and India through Unilever under license.

DreaMed Diabetes

DreaMed Diabetes provides diabetes patients with personalized and expert level care when and where needed using advanced algorithms and analytics designed by the world’s leading endocrinologists. It uses all relevant patient data to deliver holistic treatment plan recommendations at the point of care and in between patient visits.

DreaMed’s first product launch is endo.digital, a cloud-based SAAS platform that gives care provider organizations an end-to-end diabetes care pathway that can be deployed across all care settings where patients with diabetes are treated, both remotely and in person. It is the only decision support software cleared by the FDA to support both Type 1 and Type 2 diabetes.

DIA Imaging

DiA is the leading provider of AI-powered ultrasound analysis software that solves the two main challenges ultrasound users are struggling with today: how to capture the right image and how to analyze it correctly.​

DiA’s AI auto solutions use advanced pattern recognition, deep learning and machine learning algorithms to automatically imitate the way the human eye identifies borders and motion.

The solutions are vendor-neutral and run on images from any ultrasound device (mobile and portable devices), and cross-platform that can be added to any ultrasound device, Healthcare IT system, or work behind the scenes.

Gerium Medical / Redworth

Gerium Medical is the developer of BiliCare, a noninvasive bilirubin meter for newborns. BiliCare's technology is based on spectroscopy, and involves measuring substances using visible and non-visible light at varying wavelengths. The device is CE-marked and used for neonatal jaundice diagnosis.

Gerium Medical was acquired by Redworth Israel Ltd. in 2015 and now operates under the Mennen Medical Group.

Bonfix

Bonfix is developing a minimally invasive device for the correction of hallux valgus, or bunions, currently treated with osteotomies and manipulation of bone fragments, which entail pain, long recovery times, and high recurrence.
Bonfix aims to replace this operation with a minimally invasive procedure involving ambulatory surgery and minor functional limitations.

Lydus Medical

Lydus Medical specializes in the field of Microsurgery developing a novel system for automating the creation of a safe, simple and fast anastomosis.

Lydus has developed Vesseal™ , an automated microvascular suturing device delivering thread only standardized omni-vessel anastomoses, to enable simple, fast, easy, safe and effective procedures.

TriSol Medical

TriSol Medical develops a prosthetic percutaneous tricuspid valve replacement.

The TriSol valve is constructed with a Nitinol frame and specially designed leaflets.

Its design provides a comprehensive solution to the unique anatomical and functional challenges that arise when treating tricuspid regurgitation with a replacement valve.

Vibrant

Vibrant Gastro is the developer of the Synchronized Activation Method, a groundbreaking drug-free technology system that uses gentle vibrations to stimulate the colon mechanically. The preprogrammed timing of the mechanical stimulation is designed to improve natural colonic motility by leveraging the colon’s biological clock.
The company’s technology system allows for future development of data-driven personalized treatments and additional indications leveraging the gut-brain connection via the enteric nervous system pathway.

Vibrant Gastro’s first indication is for treating adults with chronic idiopathic constipation who have not experienced relief of their symptoms after using laxative therapies at the recommended dosage for at least one month.

Nitiloop/Microbot Medical

Nitiloop developed NovaCross, a microcatheter that enables guidewire positioning and distal support, with an extendable segment for additional support. The NovaCross, comprising a competent supporting microcatheter and a low-profile microcatheter, uses an operator-controlled nitinol scaffold and an extendable segment, both at its distal tip.

The FDA-cleared NovaCross family of microcatheters, includes NovaCross CTO for chronic total occlusion treatment, NovaCross Xtreme and NovaCross BTK for below-the-knee treatment. The NovaCross devices are intended to facilitate the intraluminal placement of conventional and steerable guidewires beyond stenotic lesions, including chronic total occlusions before percutaneous transluminal coronary angioplasty or stent intervention.

Nitillop was acquired by Microbot Medical on 2022.

CTG Pharma

CTG Pharma's solution enables chimeric antigen receptor (CAR) T therapy for HER2-positive solid tumors while mitigating toxicity and on-target off-tumor reactions. CTG Pharma's solutions include a library of 65,000 promoters that enable safer CAR T for the treatment of solid tumors, applicable to any CAR and suitable for a variety of tumor micro-environment conditions.

CTG Pharma aims to create a broadly applicable platform to enhance the safety and efficacy of a variety of human CAR T therapies requiring regulation of CAR expression. The platform is composed of a rationally designed library of 65,000 different switches, for minimal immune response in healthy tissues and maximum expression of the CAR specifically in the tumor surroundings. It is a highly sensitive system that integrates unique signals from the solid tumor microenvironment for the regulation of CAR expression. The company's first line of products is HER2-positive cancers.

Nervio

Nervio is a digital health start-up applying data science and artificial intelligence in the field of neurophysiology. The company's mission is to prevent avoidable paralysis and severe neurologic complications during surgery.

Nervio's AI-powered neuromonitoring solution alerts clinicians in real time to any neurological complications right in the operating room, thus minimizing permanent nerve injuries.

Cetrieve

Ceretrieve developed CathTrap, a neurothrombectomy system with integrated embolic protection for ischemic stroke endovascular treatment. CathTrap provides physicians with a safe, easy-to-use device to prevent distal embolization during thrombectomy procedures for better treatment efficiency and improved clinical outcomes for patients.

Ceretrieves aspiration catheter has an expandable soft tip that can enlarge its diameter from 6F to the clot size in order to provide a powerful aspiration force to extract and ingest the clot without compromising trackability in reaching the clot.

CannaMore

CannaMore is a clinical-stage research platform company committed to the development of novel and improved cannabis-based treatment options that will potentially benefit millions of patients worldwide.

The company is focusing on the development of a CBD-based formulation for the treatment of bronchiolitis obliterans, and inflammatory bowel diseases with its proprietary enema formulation. It is in clinical phase 2 for these indications.

Stero Biotechs

STERO Biotechs is a clinical-stage company that researches and develops novel and improved treatment solutions designed to benefit patients by reducing the side effects of and need for steroid therapy.

STERO uses cannabidiol (CBD), a non-psychotropic component of cannabis sativa, which has been shown to possess potent immunomodulatory and anti-inflammatory properties in a variety of indications.

The company has completed several clinical trials, including phase 2a clinical trials for steroid dependent Crohns disease (IBD), for chronic urticaria (hives), and severe COVID-19 with promising results.

CannaLean

CannaLean Biotechs is committed to the research and development of a proprietary formulation of cannabidiol (CBD) and chitosan that can potentially benefit millions of patients with dyslipidemia.

CannaLean uses a synthetic form of CBD, a non-psychotropic component of cannabis, with chitosan, a biocompatible, non-toxic, and non-immunogenic compound that enhances the potential of CBD to reduce lipid blood levels. The company's preliminary results show the effect of the formulation on cholesterol and triglyceride reduction.

CannaLean's patent covers a composition of CBD and chitosan for improving dyslipidemia and other signs and symptoms of metabolic syndrome.

MIndtension

MindTension offers an affordable, ultra-precise, rapid diagnostic platform that measures signs of ADHD in just six minutes. MindTension uses an electromyography (EMG) system to measure reflexive responses to auditory stimuli and levels of inhibition: the more exaggerated the response, or the lower the level of inhibition, the more serious the condition.

The company’s accurate, in-office diagnostic procedure enables therapists to immediately measure the effects of ADHD medication and make adjustments in order to identify the smallest dose required to produce the desired outcome.

HARP

HARP Diagnostics is developing an easy-to-use monitoring device for people with Inflammatory Bowel Disease (IBD), for superior disease control.

Regularly and accurately monitoring for early signs of bowel inflammation is vital to optimizing treatment, yet patient compliance with current monitoring options is very low due to their unpleasantness and complexity for the home user.

Laryngoport

Laryngoport offers a flexible endoscopic platform for performing laryngeal microsurgical procedures. The platform provides greater visualization and better surgical access to any required site, resulting in greater precision and safer procedures with less tissue damage and significantly higher efficiency than traditional laryngeal microsurgical procedures.

Smartest

Startest is developing an easy-to-use test to detect blood glucose levels in prediabetic patients. The test is designed to be for one-time use and is compatible with an online platform. The test has the same precision as a regular glucose meter, but is administered through Smartest’s patent needle mechanism, which is less painful to patients than traditional blood glucose testing.

MedAware

MedAware has developed a medication safety monitoring platform that identifies patient- and provider-specific risks that might otherwise be missed by existing tools and systems.

MedAware’s AI engine is used to provide a personalized look at the appropriateness of a patient’s medication therapy at each stage of their treatment journey, identifying prescribing anomalies that could put the patient, provider, care team, and health institution at risk.

MedAware’s AI engine is powered by advanced machine-learning algorithms and outlier-detection mechanisms similar to those trusted by financial institutions for fraud detection.

BlinkAid

BlinkAid develops a wearable application for the prevention and alleviation of Dry Eye and Computer Vision Syndromes’ burden. Taking an innovative and bold approach, leveraging novel physiological mechanisms of action, BlinkAid makes use of glasses frames as a platform. BlinkAid’s patent protected technology, embedded onto the users’ personal glasses, monitor the rate and quality of blinks to compensate for improper blinking using highly specific and personally tailored neurostimulation. In practice BlinkAid is to be the first to make use of the glasses for medical aid other than vision correction and the first to address Dry Eye Symptoms via the natural mechanism of blinking.

OphtiMedRx

OphtiMedRx LTD is an ophthalmic drug development company supported by Galil Ofek Ventures and RunYoung organization. The company is developing a novel innovative molecular pharmacotherapy for dry Age-related Macular Degeneration (AMD), a common eye disease leading to blindness.

OphtimedRx is developing an anti-senescence (cellular aging) agent for the treatment of dry AMD, based on the modern approach of facing senescent cells as a target for age related diseases. This novel senotherapy strategy should play a prominent role in the treatment and prevention of this incurable, blinding disease.

The company's innovative therapy would prevent gradual loss of vision, loss of independence, maintain the ability to perform everyday tasks, and bring enormous benefit to patients.

VESSL

When vascular-related conditions don’t respond to treatment, or conventional therapies aren’t an option, they can be devastating. They compromise people’s quality of life, drain them of hope for the future and may cause death while costing the healthcare system billions of dollars.

VESSL is using cell- and gene-based proprietary technologies along with the body’s own healing mechanisms to develop solutions for vascular-related conditions that are effective and faster to recover from. Their breakthrough solutions are aimed for people suffering from advanced peripheral arterial disease, problems with their dialysis access sites and many other conditions.

APX

APX Ophthalmology has created a safe, easy-to-use pupil dilator and expander that is fast and simple to insert and remove, requires no intraocular manipulations, and does not impede surgical instruments within the surgical field.

The scissor-like device is designed to increase efficiency, with blunt, rounded terminal tips on the internal side and a Nitinol spring on the outer side. The device is designed to provide surgeons with effective pupil dilation, comfortable surgical performance, and a high safety profile in eyes with small pupils or floppy iris syndrome.

Dio Tree

Dio Tree develops a novel, first in class, small molecule for the treatment of ovarian cancer. The new technology is based on inhibition of the enzyme DIO3, which is a major driver in many types of cancer, and specifically, in ovarian cancer.

Dio Tree is part of NGT HealthCare II incubator